Trial · NCT03181503
Results by group242
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 242
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 2 | -0.6 | Standard Deviation 1.21 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 2 | -3.4 | Standard Deviation 2.38 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 4 | -1.2 | Standard Deviation 1.33 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 4 | -4.3 | Standard Deviation 2.77 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 8 | -1.6 | Standard Deviation 1.62 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 8 | -4.7 | Standard Deviation 2.90 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 12 | -1.5 | Standard Deviation 1.84 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 12 | -5.1 | Standard Deviation 2.95 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 16 | -1.7 | Standard Deviation 1.81 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 16 | -5.1 | Standard Deviation 3.00 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 18 | -1.8 | Standard Deviation 1.87 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 18 | -4.9 | Standard Deviation 3.07 | Units on a scale |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 1 | -7.5 | Standard Deviation 12.82 | Percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 1 | -26.6 | Standard Deviation 21.25 | Percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 2 | -9.6 | Standard Deviation 15.28 | Percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 2 | -44.0 | Standard Deviation 29.54 | Percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 4 | -16.5 | Standard Deviation 18.25 | Percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 4 | -53.4 | Standard Deviation 33.23 | Percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 8 | -24.6 | Standard Deviation 23.38 | Percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 8 | -57.3 | Standard Deviation 34.78 | Percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03181503/results?page=2